Literature DB >> 20726768

Survival of hepatitis C virus in syringes: implication for transmission among injection drug users.

Elijah Paintsil1, Huijie He, Christopher Peters, Brett D Lindenbach, Robert Heimer.   

Abstract

BACKGROUND: We hypothesized that the high prevalence of hepatitis C virus (HCV) among injection drug users might be due to prolonged virus survival in contaminated syringes.
METHODS: We developed a microculture assay to examine the viability of HCV. Syringes were loaded with blood spiked with HCV reporter virus (Jc1/GLuc2A) to simulate 2 scenarios of residual volumes: low void volume (2 microL) for 1-mL insulin syringes and high void volume (32 microL) for 1-mL tuberculin syringes. Syringes were stored at 4 degrees C, 22 degrees C, and 37 degrees C for up to 63 days before testing for HCV infectivity by using luciferase activity.
RESULTS: The virus decay rate was biphasic (t1/2alpha= 0.4 h and t1/2beta = 28 hh). Insulin syringes failed to yield viable HCV beyond day 1 at all storage temperatures except 4 degrees , in which 5% of syringes yielded viable virus on day 7. Tuberculin syringes yielded viable virus from 96%, 71%, and 52% of syringes after storage at 4 degrees, 22 degrees, and 37 degrees for 7 days, respectively, and yielded viable virus up to day 63.
CONCLUSIONS: The high prevalence of HCV among injection drug users may be partly due to the resilience of the virus and the syringe type. Our findings may be used to guide prevention strategies.

Entities:  

Mesh:

Year:  2010        PMID: 20726768      PMCID: PMC2932767          DOI: 10.1086/656212

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  46 in total

1.  Community characteristics associated with HIV risk among injection drug users in the San Francisco Bay Area: a multilevel analysis.

Authors:  Ricky N Bluthenthal; D Phuong Do; Brian Finch; Alexis Martinez; Brian R Edlin; Alex H Kral
Journal:  J Urban Health       Date:  2007-07-27       Impact factor: 3.671

2.  Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention.

Authors:  Stephen Koester; Jason Glanz; Anna Barón
Journal:  AIDS Behav       Date:  2005-03

3.  Can home-made injectable opiates contribute to the HIV epidemic among injection drug users in the countries of the former Soviet Union?

Authors:  Nadia Abdala; Jean-Paul C Grund; Yanis Tolstov; Andrei P Kozlov; Robert Heimer
Journal:  Addiction       Date:  2006-05       Impact factor: 6.526

4.  Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged 18-30 years, 1994-2004.

Authors:  Richard D Burt; Holly Hagan; Richard S Garfein; Keith Sabin; Cindy Weinbaum; Hanne Thiede
Journal:  J Urban Health       Date:  2007-05       Impact factor: 3.671

5.  Infectivity of hepatitis C virus in plasma after drying and storing at room temperature.

Authors:  Saleem Kamili; Kris Krawczynski; Karen McCaustland; Xiaofang Li; Miriam J Alter
Journal:  Infect Control Hosp Epidemiol       Date:  2007-04-16       Impact factor: 3.254

6.  Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000.

Authors:  Fan-Chen Tseng; Thomas R O'Brien; Mingdong Zhang; Alex H Kral; Betty A Ortiz-Conde; Jennifer Lorvick; Michael P Busch; Brian R Edlin
Journal:  Hepatology       Date:  2007-09       Impact factor: 17.425

7.  Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus.

Authors:  Christopher T Jones; Catherine L Murray; Dawnnica K Eastman; Jodie Tassello; Charles M Rice
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

8.  Complete replication of hepatitis C virus in cell culture.

Authors:  Brett D Lindenbach; Matthew J Evans; Andrew J Syder; Benno Wölk; Timothy L Tellinghuisen; Christopher C Liu; Toshiaki Maruyama; Richard O Hynes; Dennis R Burton; Jane A McKeating; Charles M Rice
Journal:  Science       Date:  2005-06-09       Impact factor: 47.728

9.  Pandemic influenza preparedness: the critical role of the syringe.

Authors:  Kenneth Strauss; André van Zundert; Anders Frid; Vincenzo Costigliola
Journal:  Vaccine       Date:  2006-03-20       Impact factor: 3.641

10.  Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro.

Authors:  Brett D Lindenbach; Philip Meuleman; Alexander Ploss; Thomas Vanwolleghem; Andrew J Syder; Jane A McKeating; Robert E Lanford; Stephen M Feinstone; Marian E Major; Geert Leroux-Roels; Charles M Rice
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-16       Impact factor: 11.205

View more
  62 in total

1.  Novel mutations in a tissue culture-adapted hepatitis C virus strain improve infectious-virus stability and markedly enhance infection kinetics.

Authors:  Maria V Pokrovskii; Caroline O Bush; Rudolf K F Beran; Margaret F Robinson; Guofeng Cheng; Neeraj Tirunagari; Martijn Fenaux; Andrew E Greenstein; Weidong Zhong; William E Delaney; Matthew S Paulson
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

2.  Hepatitis C virus serosorting in people who inject drugs: sorting out the details.

Authors:  Arthur Y Kim; Kimberly Page
Journal:  J Infect Dis       Date:  2013-10-16       Impact factor: 5.226

3.  Inactivation and survival of hepatitis C virus on inanimate surfaces.

Authors:  Juliane Doerrbecker; Martina Friesland; Sandra Ciesek; Thomas J Erichsen; Pedro Mateu-Gelabert; Jörg Steinmann; Jochen Steinmann; Thomas Pietschmann; Eike Steinmann
Journal:  J Infect Dis       Date:  2011-10-19       Impact factor: 5.226

4.  A time since onset of injection model for hepatitis C spread amongst injecting drug users.

Authors:  S Corson; D Greenhalgh; S J Hutchinson
Journal:  J Math Biol       Date:  2012-08-28       Impact factor: 2.259

5.  Detachable low dead space syringes for the prevention of hepatitis C among people who inject drugs in Bristol, UK: an economic evaluation.

Authors:  Elizabeth Hancock; Zoe Ward; Rachel Ayres; Jane Neale; Deborah Hussey; Joanna May Kesten; Matthew Hickman; Peter Vickerman
Journal:  Addiction       Date:  2019-11-19       Impact factor: 6.526

Review 6.  Global control of hepatitis C: where challenge meets opportunity.

Authors:  David L Thomas
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

Review 7.  people who inject drugs, HIV risk, and HIV testing uptake in sub-Saharan Africa.

Authors:  Alice K Asher; Judith A Hahn; Marie-Claude Couture; Kelsey Maher; Kimberly Page
Journal:  J Assoc Nurses AIDS Care       Date:  2012-11-17       Impact factor: 1.354

8.  HEPATITIS C VIRUS GENOTYPES IN INJECTING DRUG USERS FROM ROMANIA.

Authors:  Camelia Sultana; Codruta Vagu; Aura Temereanca; Camelia Grancea; Josefina Slobozeanu; Simona Ruta
Journal:  Cent Eur J Med       Date:  2011-10

9.  Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.

Authors:  Matthew J Akiyama; Charles M Cleland; John A Lizcano; Peter Cherutich; Ann E Kurth
Journal:  Lancet Infect Dis       Date:  2019-09-17       Impact factor: 25.071

Review 10.  Epidemiology of hepatitis C in Croatia in the European context.

Authors:  Tatjana Vilibic-Cavlek; Jasmina Kucinar; Bernard Kaic; Maja Vilibic; Nenad Pandak; Ljubo Barbic; Vladimir Stevanovic; Jasmina Vranes
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.